On December 1st Rosemont Pharmaceuticals received Marketing Authorisation for Glycopyrronium Bromide 1mg/5ml Oral Solution. This prescription only medicinal product is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialorrhoea, or chronic pathological drooling, is the unintentional loss of saliva from the mouth and is most commonly caused by neuromuscular conditions.
Rosemont specialises in liquid medicines and has been manufacturing liquid medicines in the UK for over 50 years.
Rosemont Pharmaceuticals Ltd. Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE
DTM352 Date of Preparation: December 2021